NCT07787689Not yet recruiting
Intermittent vs Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne Muscular Dystrophy
Efficacy and Safety of Intermittent vs. Alternate Daily Regimen of Prednisolone in Ambulatory Boys With Duchenne Muscular Dystrophy: A Randomized, Open-Label Trial
Source: ClinicalTrials.gov · Last updated 26 Aug 2026
Brief summary (registry, in English)
The alternate-day regimen is hypothesized to reduce hypothalamic-pituitary-adrenal (HPA) axis suppression and decrease steroid-related toxicity. Similarly, intermittent regimens aim to provide periodic steroid exposure sufficient for muscle preservation while allowing recovery periods to limit side effects. There is a critical need for localized, prospective data to determine which protocol offers the optimal balance of efficacy and safety for pediatric patients in Pakistan.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 22 Aug 2026
- Start date
- 15 Sept 2026
- Primary completion date
- 15 Mar 2027
- Lead sponsor
- Muhammad Aamir Latif
- Diseases
- Duchenne muscular dystrophy
- NCT number
- NCT07787689
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 15 Sept 2026 to the primary completion date, 15 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with pre-existing cardiopulmonary failure
Other
- Patients entirely unable to perform baseline ambulatory assessments (non-ambulatory)
- Patients with clinically suspected muscular dystrophy with normal genetic study for DMD
Who the study is looking for
- Male patients
- Aged 4-10 years
- 2\. Confirmed diagnosis of DMD (via genetic testing and significantly elevated creatine kinase (CK) levels \>1000 U/L with typical clinical presentation)
Age in the registry: 4 years to 10 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Children's Hospital/University of Child Health Sciences Coordinator of this site? Confirm its status | Lahore | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.